JP2015517988A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015517988A5 JP2015517988A5 JP2015503291A JP2015503291A JP2015517988A5 JP 2015517988 A5 JP2015517988 A5 JP 2015517988A5 JP 2015503291 A JP2015503291 A JP 2015503291A JP 2015503291 A JP2015503291 A JP 2015503291A JP 2015517988 A5 JP2015517988 A5 JP 2015517988A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- amino
- chromen
- formula
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 123
- -1 dihydrochloride Chemical compound 0.000 claims 34
- 150000001875 compounds Chemical class 0.000 claims 28
- 125000003282 alkyl amino group Chemical group 0.000 claims 26
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 26
- 125000003545 alkoxy group Chemical group 0.000 claims 20
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 19
- 125000000623 heterocyclic group Chemical group 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- 102100021947 Survival motor neuron protein Human genes 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 210000005260 human cell Anatomy 0.000 claims 8
- 101000617738 Homo sapiens Survival motor neuron protein Proteins 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 208000022074 proximal spinal muscular atrophy Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 3
- 101150015954 SMN2 gene Proteins 0.000 claims 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000005241 heteroarylamino group Chemical group 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- RNHHCWHXEGFZPM-UHFFFAOYSA-N 2-(2-fluoro-4,5-dimethoxyphenyl)-6-piperazin-1-ylchromen-4-one Chemical compound C1=C(OC)C(OC)=CC(F)=C1C1=CC(=O)C2=CC(N3CCNCC3)=CC=C2O1 RNHHCWHXEGFZPM-UHFFFAOYSA-N 0.000 claims 1
- XOGOSMWEOHZWNR-OKILXGFUSA-N 2-(3-chloro-4-methoxyphenyl)-6-[(3r,5s)-3,5-dimethylpiperazin-1-yl]chromen-4-one Chemical compound C1=C(Cl)C(OC)=CC=C1C1=CC(=O)C2=CC(N3C[C@@H](C)N[C@@H](C)C3)=CC=C2O1 XOGOSMWEOHZWNR-OKILXGFUSA-N 0.000 claims 1
- MDCKGMIDVNUYKV-UHFFFAOYSA-N 2-(3-fluoro-4-methoxyphenyl)-6-piperazin-1-ylchromen-4-one Chemical compound C1=C(F)C(OC)=CC=C1C1=CC(=O)C2=CC(N3CCNCC3)=CC=C2O1 MDCKGMIDVNUYKV-UHFFFAOYSA-N 0.000 claims 1
- RRNQJKJZEDWWRA-UHFFFAOYSA-N 2-(6-methylimidazo[1,2-a]pyrazin-2-yl)-6-piperazin-1-ylchromen-4-one Chemical compound N1=C2C=NC(C)=CN2C=C1C(OC1=CC=2)=CC(=O)C1=CC=2N1CCNCC1 RRNQJKJZEDWWRA-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 1
- HMPQVCKEXKZNHP-UHFFFAOYSA-N 6-(1,4-diazepan-1-yl)-2-(3,4-dimethoxyphenyl)chromen-4-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=CC(N3CCNCCC3)=CC=C2O1 HMPQVCKEXKZNHP-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000005100 aryl amino carbonyl group Chemical group 0.000 claims 1
- 125000001769 aryl amino group Chemical group 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 claims 1
- 230000000155 isotopic effect Effects 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 0 C=CC(C1=**=N*I=C1OC(C=*=S=C)=C)=* Chemical compound C=CC(C1=**=N*I=C1OC(C=*=S=C)=C)=* 0.000 description 24
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261614932P | 2012-03-23 | 2012-03-23 | |
| US61/614,932 | 2012-03-23 | ||
| PCT/US2013/031232 WO2013142236A1 (en) | 2012-03-23 | 2013-03-14 | Compounds for treating spinal muscular atrophy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015517988A JP2015517988A (ja) | 2015-06-25 |
| JP2015517988A5 true JP2015517988A5 (https=) | 2016-04-07 |
| JP6219921B2 JP6219921B2 (ja) | 2017-10-25 |
Family
ID=49223223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503291A Active JP6219921B2 (ja) | 2012-03-23 | 2013-03-14 | 脊髄性筋委縮症を処置するための化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9914722B2 (https=) |
| EP (1) | EP2828247B1 (https=) |
| JP (1) | JP6219921B2 (https=) |
| KR (1) | KR102109992B1 (https=) |
| CN (1) | CN104470909B (https=) |
| BR (1) | BR112014023483B1 (https=) |
| CA (1) | CA2868026C (https=) |
| EA (1) | EA028382B1 (https=) |
| MX (1) | MX358514B (https=) |
| WO (1) | WO2013142236A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX352861B (es) | 2011-12-30 | 2017-12-13 | Ptc Therapeutics Inc | Compuestos para tratar la atrofia muscular espinal. |
| MX357834B (es) | 2012-01-26 | 2018-07-26 | Ptc Therapeutics Inc | Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal. |
| EP2812004B1 (en) | 2012-02-10 | 2018-06-27 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| CA2865957C (en) | 2012-03-01 | 2020-02-11 | F. Hoffmann-La Roche Ag | Compounds for treating spinal muscular atrophy |
| CA2894992A1 (en) * | 2012-12-24 | 2014-07-03 | Ramot At Tel-Aviv University Ltd. | Agents for treating genetic diseases resulting from nonsense mutations, and methods for identifying the same |
| EP3035935B1 (en) | 2013-08-19 | 2020-03-11 | F. Hoffmann-La Roche AG | Compounds for use in the prophylaxis and treatment of cancer |
| US10195202B2 (en) | 2013-12-19 | 2019-02-05 | Ptc Therapeutics, Inc. | Methods for modulating the amount of RNA transcripts |
| US10882868B2 (en) | 2014-05-15 | 2021-01-05 | Hoffmann-La Roche Inc. | Compounds for treating spinal muscular atrophy |
| US10668171B2 (en) | 2015-05-30 | 2020-06-02 | Ptc Therapeutics, Inc. | Methods for modulating RNA splicing |
| TN2017000508A1 (en) | 2015-06-26 | 2019-04-12 | Takeda Pharmaceuticals Co | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor |
| EP3366679B1 (en) | 2015-10-20 | 2021-03-24 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EA201800367A1 (ru) | 2015-12-10 | 2019-02-28 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Способы лечения болезни хантингтона |
| JP2019535789A (ja) | 2016-11-28 | 2019-12-12 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｒｎａスプライシングを調節する方法 |
| EP3634953B1 (en) | 2017-06-05 | 2024-01-03 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
| JP2020523365A (ja) | 2017-06-14 | 2020-08-06 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｒｎａスプライシングを改変する方法 |
| CN111182898B (zh) | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| MX2019015580A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
| JP7312749B2 (ja) | 2017-08-04 | 2023-07-21 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングをモジュレートする方法および組成物 |
| JPWO2019168170A1 (ja) * | 2018-03-02 | 2021-03-04 | 国立大学法人 長崎大学 | クロモン誘導体及びアミロイド関連疾患診断用組成物 |
| EA202092001A1 (ru) | 2018-03-27 | 2021-01-29 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Соединения для лечения болезни гентингтона |
| CN112469707B (zh) | 2018-06-27 | 2024-06-21 | 利伯纳生物科学株式会社 | 脊髓性肌萎缩症的预防剂或治疗剂 |
| WO2020005877A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| EP3814360B8 (en) | 2018-06-27 | 2024-11-06 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| HRP20240935T1 (hr) | 2018-06-27 | 2024-11-22 | Ptc Therapeutics, Inc. | Heterociklični i heteroaril spojevi za liječenje huntingtonove bolesti |
| WO2020163405A1 (en) | 2019-02-05 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| JP7551629B2 (ja) | 2019-02-05 | 2024-09-17 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| JP7603595B2 (ja) | 2019-02-06 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| JP7603594B2 (ja) | 2019-02-06 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| JP7649257B2 (ja) | 2019-05-13 | 2025-03-19 | ピーティーシー セラピューティクス， インコーポレイテッド | ハンチントン病を処置するための化合物 |
| US11129829B2 (en) | 2019-06-17 | 2021-09-28 | Skyhawk Therapeutics, Inc. | Methods for modulating splicing |
| KR102823820B1 (ko) * | 2022-09-01 | 2025-06-23 | 단국대학교 천안캠퍼스 산학협력단 | 퓨로크로멘온계 화합물을 유효성분으로 포함하는 근감소증 예방 또는 치료용 약학 조성물 |
| WO2024249554A1 (en) * | 2023-05-30 | 2024-12-05 | The Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health | Multitarget small molecule inhibitors and uses thereof |
| AU2024286618A1 (en) * | 2023-06-09 | 2025-10-30 | F. Hoffmann-La Roche Ag | Inducible gene expression system |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH479607A (de) | 1967-02-27 | 1969-10-15 | Geigy Ag J R | Verfahren zur Herstellung von Areno-oxazinonverbindungen |
| US3558618A (en) | 1968-04-01 | 1971-01-26 | Dow Chemical Co | Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones |
| GB1296469A (https=) * | 1970-02-05 | 1972-11-15 | ||
| US4122274A (en) | 1977-05-25 | 1978-10-24 | Bristol-Myers Company | 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones |
| US4342870A (en) | 1980-03-28 | 1982-08-03 | Janssen Pharmaceutica N.V. | Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives |
| US5089633A (en) | 1987-04-28 | 1992-02-18 | Georgia Tech Research Corporation | Substituted isocoumarins |
| US5726182A (en) | 1990-05-02 | 1998-03-10 | Abbott Laboratories | Quinolizinone type compounds |
| US5278174A (en) | 1990-06-04 | 1994-01-11 | Scios Nova, Inc. | Sigma binding site agents |
| AU4231293A (en) | 1992-05-13 | 1993-12-13 | E.I. Du Pont De Nemours And Company | Substituted pyrido(1,2-A)pyrimidinone derivatives as fungicides |
| EP0625522B1 (en) * | 1993-05-18 | 1998-08-19 | Takeda Chemical Industries, Ltd. | Benzopyran derivatives and their use |
| US5597922A (en) | 1994-07-29 | 1997-01-28 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Glycine receptor antagonist pharmacophore |
| US6630488B1 (en) | 1998-09-21 | 2003-10-07 | Biochem Pharma, Inc. | Quinolizinones as integrin inhibitors |
| EP1857443B1 (en) | 2000-01-24 | 2012-03-28 | AstraZeneca AB | Therapeutic morpholino-substituted compounds |
| GB0205281D0 (en) | 2002-03-06 | 2002-04-17 | Novartis Ag | Organic compounds |
| WO2003104216A1 (en) | 2002-06-10 | 2003-12-18 | Acadia Pharmaceuticals Inc. | Urotensin ii receptor modulators |
| JP4646626B2 (ja) | 2002-08-16 | 2011-03-09 | アストラゼネカ アクチボラグ | ホスホイノシチド３−キナーゼβの阻害 |
| CN101260104A (zh) * | 2002-08-16 | 2008-09-10 | 阿斯利康(瑞典)有限公司 | 抑制磷酸肌醇3-激酶β |
| WO2004047766A2 (en) | 2002-11-25 | 2004-06-10 | Kaloidis Antonia C | Treatment for sma disease |
| US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
| WO2004113335A2 (en) | 2003-06-20 | 2004-12-29 | Chiron Corporation | Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents |
| AU2004289303A1 (en) | 2003-11-10 | 2005-05-26 | Synta Pharmaceuticals, Corp. | Fused heterocyclic compounds |
| ATE373659T1 (de) | 2004-05-04 | 2007-10-15 | Warner Lambert Co | Pyrrolylsubstituierte pyrido(2,3-d)pyrimidin-7- one und derivate davon als therapeutische mittel |
| WO2006045010A2 (en) * | 2004-10-20 | 2006-04-27 | Resverlogix Corp. | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| CA2595477A1 (en) | 2005-01-21 | 2006-07-27 | Janssen Pharmaceutica N.V. | Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors |
| US20090123563A1 (en) | 2005-02-07 | 2009-05-14 | Novo Nordisk A/S | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand |
| CA2617213C (en) * | 2005-07-29 | 2014-01-28 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| WO2008013997A2 (en) | 2006-07-27 | 2008-01-31 | The Trustees Of Columbia University In The City Of New York | Fluorescent substrates for monoamine transporters as optical false neurotransmitters |
| ES2539828T3 (es) | 2007-09-14 | 2015-07-06 | Naturewise Biotech & Medicals Corporation | Compuestos para la inhibición de la histona de acetilasa |
| US8008344B2 (en) | 2007-09-14 | 2011-08-30 | NatureWise Biotech and Medicals Corporation | Compounds for the inhibition of histone deacetylase |
| CA2715796C (en) | 2008-03-06 | 2015-04-28 | Rottapharm S.P.A. | 2-aryl and 2 -heteroaryl 4h-1-benzopyran-4-one-6-amidino derivatives for the treatment of arthritis, cancer and related pain |
| WO2009151546A2 (en) | 2008-05-27 | 2009-12-17 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| US8932818B2 (en) | 2008-08-13 | 2015-01-13 | Ptc Therapeutics, Inc. | Screening assays for compounds that modulate programmed ribosomal frameshifting |
| WO2010048273A2 (en) | 2008-10-21 | 2010-04-29 | President And Fellows Of Harvard College | Methods and compounds for treatment of neurodegenerative disorders |
| CN101851220A (zh) * | 2009-04-03 | 2010-10-06 | 彦臣生技药品股份有限公司 | 异戊二烯类黄酮化合物及其用途 |
| CN102812014B (zh) * | 2009-10-30 | 2016-01-20 | 多美恩医疗公司 | 新颖的肟衍生物及其作为代谢型谷氨酸受体的别构调节剂的用途 |
| PH12012500901A1 (en) | 2009-11-05 | 2016-08-05 | Rhizen Pharmaceuticals Sa | Novel benzopyran kinase modulators |
| EP2501231B1 (en) | 2009-11-20 | 2016-12-21 | Merck Sharp & Dohme Corp. | Quinolizidinone carboxamide m1 receptor positive allosteric modulators |
| CN102812023A (zh) | 2010-01-13 | 2012-12-05 | 韩国巴斯德研究所 | 抗感染吡啶并(1,2-a)嘧啶类 |
| WO2011130515A1 (en) | 2010-04-14 | 2011-10-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production |
| HRP20190128T1 (hr) | 2011-05-04 | 2019-03-08 | Rhizen Pharmaceuticals S.A. | Novi spojevi kao modulatori protein kinaza |
| MX352861B (es) | 2011-12-30 | 2017-12-13 | Ptc Therapeutics Inc | Compuestos para tratar la atrofia muscular espinal. |
| MX357834B (es) | 2012-01-26 | 2018-07-26 | Ptc Therapeutics Inc | Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal. |
| EP2812004B1 (en) | 2012-02-10 | 2018-06-27 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| CA2865957C (en) | 2012-03-01 | 2020-02-11 | F. Hoffmann-La Roche Ag | Compounds for treating spinal muscular atrophy |
-
2013
- 2013-03-14 CA CA2868026A patent/CA2868026C/en active Active
- 2013-03-14 CN CN201380027139.9A patent/CN104470909B/zh active Active
- 2013-03-14 US US14/386,524 patent/US9914722B2/en active Active
- 2013-03-14 JP JP2015503291A patent/JP6219921B2/ja active Active
- 2013-03-14 BR BR112014023483-3A patent/BR112014023483B1/pt active IP Right Grant
- 2013-03-14 EA EA201491766A patent/EA028382B1/ru not_active IP Right Cessation
- 2013-03-14 MX MX2014011233A patent/MX358514B/es active IP Right Grant
- 2013-03-14 EP EP13763520.7A patent/EP2828247B1/en active Active
- 2013-03-14 KR KR1020147029409A patent/KR102109992B1/ko active Active
- 2013-03-14 WO PCT/US2013/031232 patent/WO2013142236A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015517988A5 (https=) | ||
| JP2015511224A5 (https=) | ||
| JP2016504290A5 (https=) | ||
| JP2019514878A5 (https=) | ||
| JP2016529292A5 (https=) | ||
| PE20110575A1 (es) | INHIBIDORES DE mTOR CINASA PARA INDICADORES DE ONCOLOGIA Y ENFERMEDADES ASOCIADAS CON LA TRAYECTORIA mTOR/PI3K/AKT | |
| JP2012501312A5 (https=) | ||
| FI3406609T3 (fi) | Bisyklisiä atsayhdisteitä muskariinireseptorin agonisteina | |
| PE20110419A1 (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk | |
| PE20090674A1 (es) | Compuestos multiciclicos | |
| JP2019505595A5 (https=) | ||
| JP2011500758A5 (https=) | ||
| PE20110063A1 (es) | DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK | |
| NZ600229A (en) | Triazolopyridines | |
| PE20090288A1 (es) | Derivados de quinoxalina como inhibidores de la pi3 quinasa | |
| JP2022500402A5 (https=) | ||
| NZ592508A (en) | Pyrazine compounds as phosphodiesterase 10 inhibitors | |
| JP2015503571A5 (https=) | ||
| JP2017531039A5 (https=) | ||
| JP2010525056A5 (https=) | ||
| RU2012136643A (ru) | [5,6]- гетероциклическое соединение | |
| RU2012105284A (ru) | Спиро-аминосоединения, пригодные для лечения нарушений сна и лекарственного привыкания | |
| NZ594332A (en) | Compounds for the prevention and treatment of cardiovascular disease | |
| AU2018361828A1 (en) | Antibacterial compounds | |
| MY195669A (en) | 8-[6-[3-(Amino)Propoxy]-3-Pyridyl]-1 -Isopropyl-Imidazo[4,5-C]Quinolin-2-One Derivatives As Selective Modulators Of Ataxia Telangiectasia Mutated (Atm) Kinase For The Treatment Of Cancer |